VistaGen Therapeutics's Earnings: A Preview
Portfolio Pulse from Benzinga Insights
VistaGen Therapeutics (NASDAQ:VTGN) is scheduled to release its quarterly earnings report on February 13, 2024, with analysts expecting an EPS of $-0.30. Historical data shows mixed reactions to past earnings, with the last quarter beating estimates but resulting in an 11.07% drop in share price. Shares are currently trading at $4.9, down 23.84% over the last year, indicating a bearish sentiment among long-term shareholders.
February 12, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
VistaGen Therapeutics is expected to report an EPS of $-0.30 for the upcoming quarter. Historical performance shows volatility in stock price post-earnings, with a significant drop after the last report despite beating estimates.
Given the historical performance where VTGN's stock price dropped after beating EPS estimates, and considering the current bearish sentiment indicated by a 23.84% decline over the last year, it's likely that the stock price may experience short-term negative impact post-earnings, especially if the actual EPS does not significantly exceed expectations or if the future guidance is not strongly positive.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100